Posted by AGORACOM-JC
at 5:44 PM on Monday, February 21st, 2022
To understand Star Navigation $SNA you first have to understand the problem they are solving.
At any given time 200-300 planes can be off the grid when flying and no one knows where they are. In an era in which GPS can easily track dogs, trains and automobiles, it’s hard to imagine that airplane tracking systems are not the strongest of all.
The Malaysian Air Flight 370 and Air France 447 disasters showed the world the weakness in plane monitoring systems … and the strong need for a real solution.
ENTER STAR NAVIGATION SYSTEMS
$SNA is a Flight Sciences Company that bridges the gap between flight experience and flight safety in real-time. In layman terms, that means the Company’s technology provides a continuous connection between planes and the ground … and the result is more than just tracking:
● Real-Time Aircraft Health and Engine Condition Monitoring
● Fuel Management System
● Fleet Management … and more
The Company’s flagship product is the STAR Airborne Data Service (STAR-ADS) which is powered by the patented STAR In-Flight Safety Monitoring System (STAR-ISMS).
Every two years, high-level government and military delegations, as well as senior corporate executives around the world attend the Singapore Airshow. As Asia’s largest Airshow, it is the place to be for leading aerospace companies and budding players eager to make their mark in the international aerospace and defense market.
Building on the Company’s progress at the Dubai Airshow, Star Navigation went into the Singapore Airshow with momentum and confidence – and if this interview is any indication, it appears that shareholders can expect meaningful sales results in 2022.
Sit back and watch this powerful AGORACOM Exclusive with Star Navigation Systems!
We are pleased to unveil our clinic design concept to accommodate the unique requirements of psychedelic-assisted psychotherapy. The design concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.
Inclusive and welcoming, the design concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:
Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA
To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.
“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”
Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”
To see renderings of the Design Concept, click here.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Amy de la Garza. Amy is the Substance Use Disorder Program Director at Novamind and the Medical Director of the Salt Lake City clinic. Amy is a board-certified family practice physician who for the last 10 years has been providing specialized integrative healthcare for behavioral health, substance use, and a variety of other conditions.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss qualities and skills they think are essential for therapists who provide psychedelic-assisted psychotherapy.
We’re celebrating 8 months of the podcast with a GIVEAWAY on Instagram! Enter to win a sweatshirt featuring the audio waves from a fan-favorite episode of Psychedelic Therapy Frontiers.
This is big news for Canada overall. “Long-awaited amendments to Health Canada’s Special Access Program have finally been made, potentially opening the door to less onerous access to the medical access of psychedelics like psilocybin and MDMA for patients in need.” Our mission has always been to increase access to these life-changing therapies and drugs in safe and regulated settings. We celebrate this news and will continue to do our part to bring psychedelic medicine to as many people in need as possible.
PSYCH covers the year in psychedelic healthcare. “2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin.” 2021 was special, but we can’t wait to work on making 2022 even more impactful for people around the world. For more great psychedelic content from PSYCH, download the third edition of the Psychedelics as Medicine Report here.
Dr. Reid Robison and the team at Novamind have spent years providing ketamine-assisted psychotherapy and seeing the positive benefits firsthand. It’s changed the lives of thousands of our patients. We recently published a story about how ketamine helped a mother struggling with severe depression and a struggling marriage. You can read it here. Seeing the results of this systematic review by the University of Exeter is both exciting and validating. “Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.”
Posted by AGORACOM-JC
at 5:25 PM on Thursday, January 6th, 2022
The global e-commerce market surpassed $9 TRILLION in 2019 … and is scheduled to grow by a CAGR of 14% into 2027 … But mega brands control almost 70% of the US market alone and are using their strength to win even more market … making it harder for SMBs to compete in this massive market.
Logiq …. a public company for just 4 months…. is an award-winning e-commerce and fintech solutions company that is addressing that problem by helping drive e-commerce for SMBs around the world … with revenues of $37.9M in 2020 …. from 2 divisions:
AppLogiq (Agreement finalized to Transfer AppLogiq Assets into Publicly Traded Subsidiary) – In Southeast Asia AL offers a mobile application development platform as-a-service which enables hundreds of thousands of SMBs to create mobile apps with little technical expertise or know-how … Offered across Southeast Asia, Europe and U.S. in 14 languages .. …. also offers a mobile fintech payment platform (PayLogiQ) and a hyper-local food delivery service (GoLogiq)
DataLogiq – provides a data-driven, end-to-end e-commerce marketing solution that integrates AI to help SMBs in need of online marketing solutions.
Financial Highlights:
2020 revenue of $37.9 million … 31% CAGR since 2016
Revenue H1-21 $16.4 million
Revenue Q2-21 $8.3 million …
margin of 29.5%
up 16.4 percentage points from the year-ago quarter.
Revenue Q3-21 $7.8 million
margin for DataLogiq: improved from 18.9% to 28.2%.
margin for AppLogiq: improved from 12.1% to 31.7%.
Q4-21 Revenue Estimate: $12.3 million, up 87% vs Q4-20
Gross margin expected to 34.0% vs 29.5% in the previous Q / 21.1% in Q4-20
Brent Suen, president of Logiq commented,
“Our improving revenue performance throughout 2021 demonstrates our team’s commitment to driving a transformation of our business overall and providing visibility on future profitability. As we refocused our efforts on higher quality, more profitable revenue streams and adjusted to the changing market dynamics, we also drove strong gross margin improvement every quarter of 2021. In fact, our gross margin more than doubled in Q4 2021 compared to the full year of 2020.”
Suen continued,
“We believe this strong progress across the board is keeping us on the path to profitability for both of our business segments,” continued Suen. “It also advances our plans to separate our DataLogiq and AppLogiq businesses into two independent publicly traded companies as another way to further unlock shareholder value.”
Now sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 1:40 PM on Thursday, January 6th, 2022
Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.
The company released stellar a Q3 with the following highlights:
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
Record 9 months revenues at $10.2 million , up 94%
Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
Loblaws
Dominion,
Zehrs,
Fortinio’s,
Your Independent Grocer and Superstore
Steve Saviuk , CEO commented,
We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”
Posted by AGORACOM-JC
at 6:11 PM on Wednesday, January 5th, 2022
The genesis of Liquid Avatar Technologies is a global blockchain & personal identity solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified digital Identity, which also provides businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com)
And if the story ended there, that would be more than enough to build a company on.
However, as the digital universe has continued to expand, there is an ever-increasing need to verify online identity as governments and enterprises around the world prepare for the shift. For example:
In early 2021 Google announced a major shift away from precision-targeting of ads based on everything you do on the internet
The Ontario Government released its Digital Strategy, with key themes including the launch of Digital ID credentials.
“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation,
As a result, the Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem. Almost immediately, Liquid Avatar announced a big win here by partnering with the Ontario Convenience Stores Association (OCSA) To Provide Digital Age-Verification Solutions To Over 8,000 Stores.
Again, if the story ended there, Liquid Avatar would have the makings of a potentially massive tech company.
But with the rise of NFTs and the Metaverse, both of which strongly rely on digital identity, the Company continued to expand its core digital identity technology into these areas and registered major successes, including $1,000,000 in Preliminary Gross Revenues for its Aftermath Islands Metaverse.
“Our in-market businesses continued to perform above expectations for Q4, and we remain optimistic, while cautious, as these are still early days in the Company’s transformation to an active revenue organization. We have started to witness online acceptance of digital identity programs, which are at the core of all our solutions, and both avatar and metaverse activities are gaining traction, creating opportunities for early revenue there, as the industry embraces the future of Web 3.0. Our goal is to continue to create value for all our stakeholders.”
If you believe in the future of Web3 (blockchain, crypto, tokens, NFTs and the Metaverse) and looking for a small cap company to help you participation in it, then look no further than Liquid Avatar.
Watch this powerful interview with CEO David Lucatch.
Posted by AGORACOM-JC
at 4:24 PM on Thursday, December 30th, 2021
FOBI AI is a global leader in digital wallet pass technology that delivers real-time data analytics and engagement through artificial intelligence to drive customer activation and engagement in stores, stadiums, arenas, hotels and other large venues around the world.
More than just lip service, FOBI AI is firing on all cylinders. Here are just some of the highlights from December:
Posted by AGORACOM-JC
at 10:18 AM on Saturday, December 25th, 2021
The Roundup
A weekly summary of Novamind news and media
Dr. Steve Thayer with an important reminder that, for some, the holidays can be a difficult time of year for many reasons. He shares tips to care for our mental health and wellbeing over the holidays.
We are pleased to announce the signing of a definitive agreement to acquire Arizona-based Foundations for Change, a mental health practice specialized in ketamine-assisted psychotherapy, from its sole stockholder, Jeff Edelman. The transaction is subject to regulatory approvals and is expected to close in January 2022.
Opened in 2017 by Jeff Edelman, Foundations currently operates one outpatient mental health clinic in Peoria, Arizona with an annual revenue run rate in excess of US$800,000 and owns a second, larger location in Phoenix that is scheduled to open in early 2022. Foundations will temporarily operate as “Foundations for Change by Novamind” until the Company completes its recently announced rebrand. Mr. Edelman will continue in a leadership capacity as Medical Director for both clinics. Mr. Edelman is double board-certified Family Psychiatric-Mental Health Nurse Practitioner and a Child and Adolescent Psychiatric-Mental Health Clinical Nurse Specialist. As a former military combat veteran, who served in the US Army 55th Medical Co. Combat Stress Control unit, Mr. Edelman has special expertise in treating military veterans and first responders who struggle with stress and trauma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison catch up after their recent trip to the “Horizons: Perspectives on Psychedelics” conference in New York. Stay tuned next week for our last episode of 2021 and a special PTF podcast contest and giveaway.
NBC News reports on a first-of-its kind clinical trial at the University of Washington School of Medicine to treat 30 medical professionals experiencing depression with a dose of synthetic psilocybin combined with psychotherapy. Some say that even five years ago, this would have been considered taboo. “That medical researchers are turning toward psilocybin to treat colleagues is representative of a growing curiosity and acceptance of the drug among those in the medical establishment.” We’re seeing that openness, too, through our Frontline KAP clinical pilot to help healthcare workers heal.
Posted by AGORACOM-JC
at 5:20 PM on Tuesday, December 21st, 2021
We all remember the crash of “blockchain” stocks a couple of years back, which was actually a crash of blockchain pretenders who used the term to build stock promotions, as opposed to building actual blockchains.
Like the dot-com crash of 2000, which bankrupted “dot-com” companies but gave birth to the likes of Google, Amazon, Linkedin because they built actual utility and value, the same could be expected of the blockchain crash and its’ resurgence.
But Blockchain Foundry is only just getting started. The Company is building a WEB3 ecosystem on top of its powerful Sycoin blockchain which is the 2nd most secure blockchain in the world next to Bitcoin. That isn’t a typo and Web3 coin investors believe it given the fact it has traded over $13,000,000 in volume over the last 24 hours … and close to $25,000,000 in the 24 hours before that!
What do they know that small cap investors don’t know? What to Web3 investors know that isn’t being reflected in the $BCFN stock price? The short answer is .. A Lot … but luckily we were able to tear away CEO Dan Wasyluk from his coding marathons to explain exactly what we are missing by going through the Company’s power point presentation.
If you’re a small cap investor looking for exposure to the Web3 world of blockchain, coins, tokens, NFTs and more then this $BCFN presentation is a must-watch.
Posted by AGORACOM-JC
at 4:38 PM on Friday, December 17th, 2021
Valeo Pharma is already a successful, revenue-generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
Q3 Highlights:
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
Record 9 months revenues at $10.2 million , up 94%
Public reimbursement now includes Alberta , Quebec and Nova Scotia , representing approximately 37% of the Canadian population.
More than 90% private insurance coverage across Canada
Frederic Fasano, Valeo’s President and Chief Operating Officer commented,
“We are pleased to be reporting today the addition of Quebec and Nova Scotia to join Alberta on the list of provincial public coverage secured for both asthma medications. Public Reimbursement access makes a meaningful impact for asthma patients left with no coverage so far, and also simplify health care providers procedures to provide access of both medications to their patients. Enerzair and Atectura are innovative asthma therapies that are helping make asthma control a more attainable goal for Canadians asthma patients”.
